Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 12/20 | 0.56 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.44 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12477484 | 1.00 | S1PR1 (0.56) | S1PR1PPARGPPARAPPARDMAOB | |
| SCHEMBL12477191 | 0.88 | PPARG (0.47) | S1PR1PPARGPPARAPPARDMAOB | |
| SCHEMBL12477187 | 0.88 | PPARG (0.47) | S1PR1PPARGPPARAPPARDMAOB | |
| SCHEMBL12477080 | 0.84 | S1PR1 (0.42) | S1PR1PPARGPPARAPPARDMAOB | |
| SCHEMBL12476654 | 0.84 | S1PR1 (0.42) | S1PR1PPARGPPARAPPARDMAOB | |
| SCHEMBL12476941 | 0.83 | S1PR1 (0.55) | S1PR1PPARGPPARAPPARDMAOB | |
| SCHEMBL12476707 | 0.83 | S1PR1 (0.55) | S1PR1PPARGPPARAPPARDMAOB | |
| SCHEMBL12476657 | 0.81 | PPARA (0.41) | S1PR1PPARGPPARAPPARDMAOB | |
| SCHEMBL12476199 | 0.81 | S1PR1 (0.42) | S1PR1PPARGPPARAPPARDMAOB | |
| SCHEMBL12476197 | 0.81 | S1PR1 (0.42) | S1PR1PPARGPPARAPPARDMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2658851-B1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LTD (IN) | 2015-03-11 | — | — | EP | claimed |
| US-8822414-B2 | Heterocyclic compounds suitable for the treatment of dyslipidemia | CADILA HEALTHCARE LIMITED (IN) | 2014-09-02 | — | — | US | claimed |
| US-20130281366-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2013-10-24 | — | — | US | claimed |
| EP-2658851-B1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LTD (IN) | 2015-03-11 | — | — | EP | disclosed |
| US-8822414-B2 | Heterocyclic compounds suitable for the treatment of dyslipidemia | CADILA HEALTHCARE LIMITED (IN) | 2014-09-02 | — | — | US | disclosed |
| US-20130281366-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281366-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | LIPC, HMGCR, PCSK9 | S1PR1 1455/4885PPARG 161/4885PPARA 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.